Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children

Clinical and Vaccine Immunology

Volumn 15, Issue 7, 2008, Pages 1042-1053

  Forrest, Bruce D ^a   Pride, Michael W ^a   Dunning, Andrew J ^a,e   Capeding, Maria Rosario Z ^b   Chotpitayasunondh, Tawee ^c   Tam, John S ^a,d   Rappaport, Ruth ^a   Eldridge, John H ^a   Gruber, William C ^a  

^a WYETH RESEARCH   (United States)

^b RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^c QUEEN SIRIKIT NATIONAL INSTITUTE OF CHILD HEALTH   (Thailand)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INFLUENZA VACCINE; LIVE VACCINE; PLACEBO;

ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOKINE RELEASE; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFANT; INFLUENZA; INFLUENZA VIRUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; REPRODUCIBILITY; SEROCONVERSION; VIRUS STRAIN;

ADMINISTRATION, INTRANASAL; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, CELLULAR; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; PHILIPPINES; THAILAND; VACCINATION; VACCINES, ATTENUATED;

EID: 47649085021     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00397-07     Document Type: Article

References (70)

1. Anthony, D. D., H. Valdez, A. B. Post, N. L. Carlson, P. S. Heeger, and P. V. Lehmann. 2002. Comprehensive determinant mapping of the hepatitis C-specific CD8 cell repertoire reveals unpredicted immune hierarchy. Clin. Immunol. 103:264-276.
2. Ashkenazi, S., A. Vertruyen, J. Arístegui, S. Esposito, D. D. McKeith, T. Klemola, J. Biolek, J. Kühr, T. Bujnowski, D. Desgrandchamps, S. M. Cheng, J. Skinner, W. C. Gruber, B. D. Forrest, and the CAIV-T Study Group. 2006. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza virus vaccine in young children with recurrent respiratory tract infections. Pediatr. Infect. Dis. J. 25:870-879.
3. Bachmann, M. F., T. M. Kundig, H. Hengartner, and R. M. Zinkernagel. 1997. Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells: T cell memory without 'memory T cells'? Proc. Natl. Acad. Sci. USA 94:640-645.
4. Belshe, R. B. 2004. Current status of live attenuated influenza virus vaccine in the US. Virus Res. 103:177-185.
5. Belshe, R. B., K. M. Edwards, T. Vesikari, S. V. Black, R. E. Walker, M. Hultquist, G. Kemble, E. M. Connor, and the CAIV-T Comparative Efficacy Study Group. 2007. Live attenuated versus inactivated influenza virus vaccine in infants and young children. N. Engl. J. Med. 356:685-696.
6. Belshe, R. B., W. C. Gruber, P. M. Mendelman, I. Cho, K. Reisinger, S. L. Block, J. Wittes, D. Iacuzio, P. Piedra, J. Treanor, J. King, K. Kotloff, D. I. Bernstein, F. G. Hayden, K. Zangwill, L. Yan, and M. Wolff. 2000. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr. 136:168-175.
7. Belshe, R. B., W. C. Gruber, P. M. Mendelman, H. B. Mehta, K. Mahmood, K. Reisinger, J. Treanor, K. Zangwill, F. G. Hayden, D. I. Bernstein, K. Kotloff, J. King, P. A. Piedra, S. L. Block, L. Yan, and M. Wolff. 2000. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J. Infect. Dis. 181:1133-1137.
8. Belshe, R. B., P. M. Mendelman, J. Treanor, J. King, W. C. Gruber, P. Piedra, D. I. Bernstein, F. G. Hayden, K. Kotloff, K. Zangwill, D. Iacuzio, and M. Wolff. 1998. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 338:1405-1412.
9. Bernstein, E., D. Kaye, E. Abtruyn, P. Gross, and M. Dorfman. 1999. Immune response to influenza vaccination in a large healthy elderly population. Vaccine 17:82-94.
10. Bevan, M. J. 2002. Remembrance of things past. Nature 420:748-749.
11. Blazevic, V., C. M. Trubey, and G. M. Shearer. 2000. Comparison of in vitro immunostimulatory potential of live and inactivated viruses. Hum. Immunol. 61:845-849.
12. Boon, A. C. M., E. Fringuelli, Y. M. F. Graus, R. A. M. Fouchier, K. Sintnicolaas, A. M. Iorio, G. F. Rimmelzwaan, and A. D. M. E. Osterhaus. 2002. Influenza A virus specific T cell immunity in humans during aging. Virology 299:100-108.
13. Carson, M. M., D. W. Spady, J. A. Beeler, M. P. Krezolek, S. Audet, and H. F. Pabst. 2005. Follow-up of infants given measles vaccine at 6 months of age: antibody and CMI responses to MMRII® at 15 months of age and antibody levels at 27 months of age. Vaccine 23:3247-3255.
14. Centers for Disease Control and Prevention. 1998. The 1998-99 WHO influenza reagent kit for the identification of influenza isolates. Centers for Disease Control and Prevention, Atlanta, GA.
15. Centers for Disease Control and Prevention. 2001. Update: influenza activity - United States and worldwide, 2000-01 season, and composition of the 2001-02 influenza vaccine. MMWR Morb. Mortal. Wkly. Rep. 50:466-470.
16. Cheng, S. M., R. Vainionpää, P. Zhao, F. Li, A. Hu, B. Forrest, and R. Rappaport. 2004. Detection of influenza B in clinical specimens: comparison of high throughput RT-PCR and culture confirmation. Virus Res. 103:85-90.
17. Chi, X. S., T. V. Bolar, P. Zhao, R. Rappaport, and S.-M. Cheng. 2003. Cocirculation and evolution of two lineages of influenza B viruses in Europe and Israel in the 2001-2002 season. J. Clin. Microbiol. 41:5770-5773.
18. Clements, M. L., R. F. Betts, E. L. Tierney, and B. R. Murphy. 1986. Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine. J. Clin. Microbiol. 23:73-76.
19. Clover, R. D., S. Crawford, W. P. Glezen, L. H. Taber, C. C. Matson, and R. B. Couch. 1991. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses. J. Infect. Dis. 163:300-304.
20. Cox, R. J., K. A. Brokstad, and P. Ogra. 2004. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live attenuated influenza vaccines. Scand. J. Immunol. 59:1-15.
21. Dunning, A. J. 2006. A model for immunological correlates of protection. Stat. Med. 25:1485-1497.
22. Edwards, K. M., W. D. Dupont, M. K. Westrich, W. D. Plummer, Jr., P. S. Palmer, and P. F. Wright. 1994. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J. Infect. Dis. 169:68-76.
23. Evans, A. E., R. L. Simmons, R. D. Ferris, S. K. Hasell, E. Letley, and D. S. Freestone. 1979. Antibody responses to vaccination with WRL 105 strain live influenza vaccine in previously vaccinated and unvaccinated volunteers. J. Hyg. (London) 82:489-495.
24. Fox, J. P., M. K. Cooney, C. E. Hall, and H. M. Foy. 1982. Influenza virus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am. J. Epidemiol. 116:228-242.
25. 2/Hong Kong influenza vaccine. Efficacy 14 months after immunization. JAMA 217:1067-1071.
26. Gray, D., and P. Matzinger. 1991. T cell memory is short-lived in the absence of antigen. J. Exp. Med. 174:969-974.
27. Guidotti, L. G., and F. V. Chisari. 2001. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19:65-91.
28. Guthrie, T., C. G. L. Hobbs, V. Davenport, R. E. Horton, R. S. Heyderman, and N. A. Williams. 2004. Parenteral influenza vaccination influences mucosal and systemic T cell-mediated immunity in healthy adults. J. Infect. Dis. 190:1927-1935.
29. Habermehl, P., A. Lignitz, M. Knuf, H.-J. Schmitt, M. Slaoui, and F. Zepp. 1999. Cellular immune response of a varicella vaccine following simultaneous DTaP and VZV vaccination. Vaccine 17:669-674.
30. He, X.-S., M. Draghi, K. Mahmood, T. H. Holmes, G. W. Kemble, C. L. Dekker, A. M. Arvin, P. Parham, and H. B. Greenberg. 2004. T cell-dependent production of IFN-γ by NK cells in response to influenza A virus. J. Clin. Investig. 114:1812-1819.
31. He, X.-S., T. H. Holmes, C. Zhang, K. Mahmood, G. W. Kemble, D. B. Lewis, C. L. Dekker, H. B. Greenberg, and A. M. Arvin. 2006. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J. Virol. 80:11756-11766.
32. Heikkinen, T., H. Silvennoinen, V. Peltola, T. Ziegler, R. Vainionpää, T. Vuorinen, L. Kainulainen, T. Puhakka, T. Jartti, P. Toikka, P. Lehtinen, T. Routi, and T. Juven. 2004. Burden of influenza in children in the community. J. Infect. Dis. 190:1369-1373.
33. Helms, T., B. O. Boehm, R. J. Asaad, R. P. Trezza, P. V. Lehmann, and M. Tary-Lehmann. 2000. Direct visualization of cytokine-producing recall-antigen-specific CD4 memory T cells in healthy individuals and HIV patients. J. Immunol. 164:3723-3732.
34. Herremans, T. M. P. T., J. H. J. Reimerink, A. M. Buisman, T. G. Kimman, and M. P. G. Koopmans. 1999. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J. Immunol. 162:5011-5018.
35. Karzon, D. 1996. Cytotoxic T cells in influenza immunity. Semin. Virol. 7:265-271.
36. + memory T cells. J. Exp. Med. 186:859-865.
37. Lee, M. S., K. Mahmood, L. Adhikary, M. J. August, J. Cordova, I. Cho, G. Kemble, K. Reisinger, R. E. Walker, and P. M. Mendelman. 2004. Measuring antibody responses to a live attenuated influenza vaccine in children. Pediatr. Infect. Dis. J. 23:852-856.
38. Longini, I. M., and M. E. Halloran. 2005. Strategy for distribution of influenza vaccine to high-risk groups and children. Am. J. Epidemiol. 161:303-306.
39. McElhaney, J. E., S. Gravenstein, P. Krause, J. W. Hooton, C. M. Upshaw, and P. Drinka. 1998. Assessment of markers of the cell-mediated immune response after influenza virus infection in frail older adults. Clin. Diagn. Lab. Immunol. 5:840-844.
40. McElhaney, J. E., J. W. Hooton, N. Hooton, and R. C. Bleackley. 2005. Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults. Vaccine 23:3294-3300.
41. McMichael, A. J., F. M. Gotch, G. R. Noble, and P. A. Beare. 1983. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 309:13-17.
42. Mendelman, P. M., R. Rappaport, I. Cho, S. Block, W. Gruber, M. August, D. Dawson, J. Cordova, G. Kemble, K. Mahmood, G. Palladino, M. S. Lee, A. Razmpour, J. Stoddard, and B. D. Forrest. 2004. Live attenuated influenza vaccine induces cross-reactive antibody responses in children against A/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr. Infect. Dis. J. 23:1053-1055.
43. Minor, T. E., E. C. Dick, C. R. Dick, and S. L. Inhorn. 1975. Attenuated influenza A vaccine (Alice) in an adult population: vaccine-related illness, serum and nasal antibody production, and intrafamily transmission. J. Clin. Microbiol. 2:403-409.
44. Müllbacher, A., M. Lobigs, M. Alsharifi, and M. Regner. 2006. Cytotoxic T-cell immunity as a target for influenza vaccines. Lancet Infect. Dis. 6:255-256.
45. Murasko, D. M., E. D. Bernstein, E. M. Gardner, P. Gross, G. Munk, S. Dran, and E. Abrutyn. 2002. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp. Gerontol. 37:427-439.
46. National Institutes of Health. 1973. Specific immunity in influenza B. Summary of influenza workshop III. J. Infect. Dis. 127:220-236.
47. Neuzil, K. M., Y. Zhu, M. R. Griffin, K. M. Edwards, J. M. Thompson, S. J. Tollefson, and P. F. Wright. 2002. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J. Infect. Dis. 185:147-152.
48. Nichol, K. L., P. M. Mendelman, K. P. Mallon, L. A. Jackson, G. J. Gorse, R. B. Belshe, W. P. Glezen, and J. Wittes for the Live Attenuated Influenza Virus Vaccine in Healthy Adults Trial Group. 1999. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 282:137-145.
49. Ohmit, S. E., J. C. Victor, J. R. Rotthoff, E. R. Teich, R. K. Truscon, L. L. Baum, B. Rangarajan, D. W. Newton, M. L. Boulton, and A. S. Monto. 2006. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N. Engl. J. Med. 355:2513-2522.
50. Ota, M. O. C., J. Vekemans, S. E. Schlegel-Haueter, K. Fielding, H. Whittle, P.-H. Lambert, K. P. W. J. McAdam, C.-A. Siegrist, and A. Marchant. 2004. Hepatitis B immunisation induces higher antibody and memory Th2 responses in new-borns than in adults. Vaccine 22:511-519.
51. Potter, C. W., and J. S. Oxford. 1979. Determinants of immunity to influenza infection in man. Br. Med. Bull. 35:69-75.
52. Potter, C. W., R. Jennings, K. Nicholson, D. A. Tyrrell, and K. G. Dickinson. 1977. Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines. J. Hyg. (London) 79:321-332.
53. Powers, D. C., B. R. Murphy, L. F. Fries, W. H. Adler, and M. L. Clements. 1992. Reduced infectivity of cold-adapted influenza A H1N1 viruses in the elderly: correlation with serum and local antibodies. J. Am. Geriatr. Soc. 40:163-167.
54. Prentice, R. L. 1989. Surrogate endpoints in clinical trials: definition and operational criteria. Stat. Med. 8:431-440.
55. Reichert, T. A., N. Sugaya, D. S. Fedson, W. P. Glezen, L. Simonsen, and M. Tashiro. 2001. The Japanese experience with vaccinating schoolchildren against influenza. N. Engl. J. Med. 344:889-896.
56. Rennels, M. B., H. C. Meissner, and Committee on Infectious Diseases. 2002. Technical report: reduction of the influenza burden in children. Pediatrics 110:e80. www.pediatrics.org/cgi/content/full/110/6/ e80.
57. Samdal, H. H., H. Bakke, F. Oftung, J. Holst, I. L. Haugen, G. E. Korsvold, A. C. Kristoffersen, G. Krogh, K. Nord, R. Rappuoli, A. K. Berstad, and B. Haneberg. 2005. A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants. Hum. Vaccines 1:85-90.
58. Saurwein-Teissl, M., K. Zisterer, T. L. Schmitt, R. Gluck, S. Cryz, and B. Grubeck-Loebenstein. 1998. Whole virus influenza activates dendritic cells (DC) and stimulates cytokine production by peripheral blood mononuclear cells (PBMC) while subunit vaccines support T cell proliferation. Clin. Exp. Immunol. 114:271-276.
59. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:397-402.
60. Seder, R. A., and A. V. S. Hill. 2000. Vaccines against intracellular infections requiring cellular immunity. Nature 406:793-798.
61. + T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-γ ELISPOT assays for patient immune monitoring. J. Immunother. 27:298-308.
62. Svahn, A., A. Linde, R. Thorstensson, K. Karlén, L. Andersson, and H. Gaines. 2003. Development and evaluation of a flow-cytometric assay of specific cell-mediated immune response in activated whole blood for the detection of cell-mediated immunity against varicella-zoster virus. J. Immunol. Methods 277:17-25.
63. Tam, J. S., M. R. Capeding, L. C. Lum, T. Chotpitayasunondh, Z. Jiang, L. M. Huang, B. W. Lee, Y. Qian, R. Samakoses, S. Lolekha, K. P. Rajamohanan, S. N. Narayanan, C. Kirubakaran, R. Rappaport, A. Razmpour, W. C. Gruber, B. D. Forrest, and the Pan-Asian CAIV-T Pediatric Efficacy Trial Network. 2007. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr. Infect. Dis. J. 26:619-628.
64. Treanor, J., and P. F. Wright. 2003. Immune correlates of protection against influenza in the human challenge model. Dev. Biol. (Basel) 115:97-104.
65. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251-276.
66. Vernacchio, L., H. Bernstein, S. Pelton, C. Allen, K. MacDonald, J. Dunn, D. D. Duncan, G. Tsao, V. LaPosta, J. Eldridge, S. Laussucq, D. M. Ambrosino, and D. C. Molrine. 2002. Effect of monophosphoryl lipid A (MPL®) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers. Vaccine 20:3658-3667.
67. Vesikari, T., D. M. Fleming, J. F. Arístegui, A. Vertruyen, S. Ashkenazi, R. Rappaport, J. Skinner, M. K. Saville, W. C. Gruber, B. D. Forrest, and the CAIV-T Pediatric Day Care Clinical Trial Network. 2006. Safety, efficacy, and effectiveness of live attenuated, trivalent influenza vaccine against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 118:2298-2312.
68. Vesikari, T., A. Karvonen, T. Korhonen, K. Edelman, R. Vainionpää, A. Salmi, M. K. Saville, I. Cho, A. Razmpour, R. Rappaport, R. O'Neill, A. Georgiu, W. Gruber, P. M. Mendelman, B. Forrest, and the CAIV-T Transmission Study Group. 2006. A randomized, double-blind study of the safety, transmissibility, and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr. Infect. Dis. J. 25:590-595.
69. World Health Organization. 2001. Recommended composition of influenza virus vaccines for use in the 2001-2002 season. Wkly. Epidemiol. Rec. 76:58-61.
70. Zangwill, K. M., and R. B. Belshe. 2004. Safety and efficacy of trivalent inactivated influenza virus vaccine in young children: a summary for the new era of routine vaccination. Pediatr. Infect. Dis. J. 23:189-200.